Depomed To Present At Roth Capital Partners 25th Annual Growth Stock Conference

     Depomed To Present At Roth Capital Partners 25th Annual Growth Stock
                                  Conference

PR Newswire

NEWARK, Calif., March 13, 2013

NEWARK, Calif., March 13, 2013 /PRNewswire/ --Depomed, Inc. (NASDAQ:DEPO)
today announced that it will be presenting at the Roth Capital Partners 25th
Annual Growth Stock Conference at the Ritz-Carlton Hotel in Dana Point,
California.

The presentation at the Roth conference is scheduled for 11:30 am PDT (2:30 pm
EDT) on Tuesday March 19, 2013. The presentation will be webcast, and the
webcast can be accessed via the Investor Relations page of the Depomed website
at www.depomed.com. A recording of the webcast will be archived for 30 days
on the company's website.

About Depomed

Depomed, Inc. is a specialty pharmaceutical company with three approved and
marketed products. Gralise® (gabapentin) is a once-daily treatment approved
for the management of postherpetic neuralgia (PHN). Zipsor ®(diclofenac
potassium) Liquid Filled Capsules is a non-steroidal anti-inflammatory drug
(NSAID) indicated for relief of mild to moderate acute pain in adults.
Glumetza® (metformin hydrochloride extended release tablets) is approved for
use in adults with type 2 diabetes and is commercialized by Santarus, Inc. in
the United States. Depomed formulates its products and product candidates with
its proven, proprietary Acuform® drug delivery technology, which is designed
to improve existing oral medications, allowing for extended release of
medications to the upper gastrointestinal tract when dosed with food.
Additional information about Depomed may be found on its website,
www.depomed.com.

CONTACT:

August J. Moretti 

Depomed, Inc. 510.744.8000

amoretti@depomed.com

SOURCE Depomed, Inc.

Website: http://www.depomed.com
 
Press spacebar to pause and continue. Press esc to stop.